Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.72 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.64 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | IL2 | P60568 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178662 | 1.00 | TYR (0.72) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL1178664 | 1.00 | TYR (0.72) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL8388035 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL16785939 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL15533442 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL4187277 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL4187272 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL7744552 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL16689576 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A | |
| SCHEMBL7945567 | 0.98 | TYR (0.75) | TYRSLC5A1SLC5A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160129036-A1 | ADENOSINE ANALOGS AND THEIR USE | MICRODOSE THERAPEUTX INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9255121-B2 | Adenosine analogs and their use | MICRODOSE THERAPEUTX, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140038912-A1 | ADENOSINE ANALOGS AND THEIR USE | MICRODOSE THERAPEUTX, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569259-B2 | Adenosine analogs and their use | MICRODOSE THERAPEUTX, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8546557-B2 | Methods of making nucleoside tetraphosphate analogs | MICRODOSE THERAPEUTX, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110046362-A1 | METHODS OF MAKING NUCLEOSIDE TETRAPHOSPHATE | MICRODOSE THERAPEUTX, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129036-A1 | ADENOSINE ANALOGS AND THEIR USE | P2RY2, P2RY1, P2RY11 | TYR 4707/4885SLC5A1 1449/4885SLC5A2 700/4885 |
| US-20110046362-A1 | METHODS OF MAKING NUCLEOSIDE TETRAPHOSPHATE | P2RY1, P2RY6, NUDT1 | TYR 4672/4885SLC5A1 503/4885SLC5A2 767/4885 |
| US-20140038912-A1 | ADENOSINE ANALOGS AND THEIR USE | P2RY2, P2RY1, P2RY11 | TYR 4643/4885SLC5A1 1337/4885SLC5A2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.